Vericel to Report First-Quarter 2026 Financial Results on May 7, 2026
Vericel (NASDAQ:VCEL) will report first-quarter 2026 financial results on Thursday, May 7, 2026.
Rhea-AI Summary
Vericel (NASDAQ:VCEL) will report first-quarter 2026 financial results on Thursday, May 7, 2026. Management will host a conference call and live webcast at 8:30 a.m. ET to discuss results and business highlights.
Presentation slides will be available on the Investor Relations website and a replay of the webcast will be accessible until May 7, 2027. Telephone participants can dial the provided U.S. and international numbers and enter passcode 244506.
Positive
- None.
Negative
- None.
Details
News Market Reaction – VCEL
In the Apr 23 session, VCEL gained 0.09%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Earnings release date
- May 7, 2026
- Scheduled first-quarter 2026 financial results announcement
- Conference call time
- 8:30 a.m. ET
- Time of Q1 2026 results conference call and webcast
- Webcast replay duration
- Until May 7, 2027
- Availability of replay of the earnings call webcast
- US dial-in number
- 800-330-6730
- Telephone access for the earnings conference call
- International dial-in
- +1-312-471-1351
- International access for the earnings conference call
- Call passcode
- 244506
- Passcode required to join the Q1 2026 call by phone
Previous Earnings date Reports
-
Announcement of Q4 and full-year 2025 results date and webcast details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until May 7, 2027.
To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connected, please use passcode: 244506.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.